CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.5% – Should You Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP)’s share price fell 0.5% on Monday . The stock traded as low as $43.25 and last traded at $43.70. 525,122 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 2,299,289 shares. The stock had previously closed at $43.92.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of research reports. Truist Financial upped their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Barclays raised their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Trading Down 3.7 %

The stock has a fifty day simple moving average of $42.49 and a 200-day simple moving average of $45.93. The company has a market capitalization of $3.63 billion, a PE ratio of -9.68 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In related news, Director John Greene purchased 7,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Capital Market Strategies LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $461,000. KBC Group NV grew its position in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after purchasing an additional 57,696 shares during the last quarter. Geode Capital Management LLC increased its stake in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares during the period. State Street Corp raised its holdings in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth about $1,825,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.